QIAGEN Launches QIAwave Portfolio of Environmentally Friendly Products
19 January 2022 - 8:05AM
Business Wire
- New extraction kits reduce use of plastics by up to 63% and
cardboard by up to 42% compared to QIAGEN standard kits
- Three offerings are first of a wave of sustainability-driven
product innovations
- Company reduces plastic transportation packaging material by 9%
in 2021 and is aiming for further reductions
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today
announced its new QIAwave product line by launching three nucleic
acid extraction kits that use fewer components and produce less
waste than existing ones. They are the first of their type to use
both recycled plastics and space-saving chemical concentrates.
The QIAwave RNA Mini Kit, QIAwave DNA Blood & Tissue Kit and
QIAwave Plasmid Miniprep Kit use up to 63% less plastic and up to
42% less cardboard than QIAGEN’s most popular kits for extracting
DNA, RNA and plasmid DNA from samples. That makes them a more
sustainable alternative to existing products – a major step in
reducing the environmental impact of QIAGEN’s overall
portfolio.
“QIAwave products are designed in collaboration with our
customers to tackle the persistent problem of laboratory waste
faced by scientists all over the world,” said Thomas Schweins,
Senior Vice President, Head of Life Sciences. “These three kits are
the first in a wave of continuous improvements and product
evolutions that will reduce the environmental footprint of our
products, while still delivering the same QIAGEN quality.”
The new QIAwave products feature fewer components, waste tubes
made from 100% recycled plastic, and suitable buffer concentrates
in smaller bottles, rather than ready-to-go mixes. More compact
kits and new ways of packing them reduce the amount of cardboard
needed to box them up. Instructions for re-using some components
are available online.
QIAGEN aims to reduce plastic transportation packaging waste by
a further 9% in 2022, having cut it by 9.6% in 2021. The company
has striven to reduce its plastic footprint since the formation of
its Plastic Footprint Task Force in 2018 – for example, by
replacing expanded-polystyrene boxes for cooled shipments with
recyclable alternatives and other forms of plastic packaging with
more eco-friendly alternatives.
Reducing its plastic footprint is just one aspect of QIAGEN’s
sustainability initiatives. The company has pledged to cut carbon
emissions in line with a science-based target to reach “net-zero”
by 2050, and constantly monitors its environmental impact, economic
influence and corporate citizenship around the world. The
sustainability agency ISS ESG has given QIAGEN its top-flight
“Prime” rating.
More information about QIAwave can be found here.
More information about QIAGEN’s vision of a sustainable future
can be found here.
About QIAGEN
QIAGEN N.V., a Netherlands-based holding company, is the leading
global provider of Sample to Insight solutions that enable
customers to gain valuable molecular insights from samples
containing the building blocks of life. Our sample technologies
isolate and process DNA, RNA and proteins from blood, tissue and
other materials. Assay technologies make these biomolecules visible
and ready for analysis. Bioinformatics software and knowledge bases
interpret data to report relevant, actionable insights. Automation
solutions tie these together in seamless and cost-effective
workflows. QIAGEN provides solutions to more than 500,000 customers
around the world in Molecular Diagnostics (human healthcare),
Applied Testing (primarily forensics), Pharma (pharma and biotech
companies) and Academia (life sciences research). As of December
31, 2021, QIAGEN employed more than 6,000 people in over 35
locations worldwide. Further information can be found at
http://www.qiagen.com.
Forward-Looking Statement
Certain statements contained in this press release may be
considered forward-looking statements within the meaning of Section
27A of the U.S. Securities Act of 1933, as amended, and Section 21E
of the U.S. Securities Exchange Act of 1934, as amended. To the
extent that any of the statements contained herein relating to
QIAGEN's products, collaborations markets, strategy or operating
results, including without limitation its expected adjusted net
sales and adjusted diluted earnings results, are forward-looking,
such statements are based on current expectations and assumptions
that involve a number of uncertainties and risks. Such
uncertainties and risks include, but are not limited to, risks
associated with management of growth and international operations
(including the effects of currency fluctuations, regulatory
processes and dependence on logistics), variability of operating
results and allocations between customer classes, the commercial
development of markets for our products to customers in academia,
pharma, applied testing and molecular diagnostics; changing
relationships with customers, suppliers and strategic partners;
competition; rapid or unexpected changes in technologies;
fluctuations in demand for QIAGEN's products (including
fluctuations due to general economic conditions, the level and
timing of customers' funding, budgets and other factors); our
ability to obtain regulatory approval of our products; difficulties
in successfully adapting QIAGEN's products to integrated solutions
and producing such products; the ability of QIAGEN to identify and
develop new products and to differentiate and protect our products
from competitors' products; market acceptance of QIAGEN's new
products and the integration of acquired technologies and
businesses. For further information, please refer to the
discussions in reports that QIAGEN has filed with, or furnished to,
the U.S. Securities and Exchange Commission (SEC).
Category: Corporate
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220118006125/en/
QIAGEN:
Investor Relations John Gilardi +49 2103 29 11711 Phoebe
Loh +49 2103 29 11457 e-mail: ir@QIAGEN.com
Public Relations Thomas Theuringer +49 2103 29 11826
e-mail: pr@QIAGEN.com
Qiagen NV (NYSE:QGEN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Qiagen NV (NYSE:QGEN)
Historical Stock Chart
From Jul 2023 to Jul 2024